Sort
10,766 grants matching “checkpoint inhibitor”
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction
$520,926Amy E Moran · Oregon Health & Science University · R37 · FY2024 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$520,857Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$520,857Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$520,857Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2019 · CA
FEEDBACK CONTROL OF THE CELL CYCLE
$520,780Andrew W Murray · Harvard University · R37 · FY2008 · GM
Plk1 as a prognostic biomarker for prostate cancer
$520,626Xiaoqi Liu · University Of Kentucky · R01 · FY2024 · CA
Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling
$520,600Jae-Il Park · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Developing new therapeutic strategies for brain metastasis
$520,544Eva Hernando · New York University School Of Medicine · R01 · FY2024 · CA
PAG is a novel target in immunotherapy
$520,485Adam Mor · Columbia University Health Sciences · R01 · FY2022 · AI
First in Human Trials of ProAgio, a Cytotoxin
$520,441Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Okazaki fragment maturation: mutagenesis and cell survival
$520,411Binghui Shen · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$520,309Xiaoxia Li · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$520,309Thaddeus S Stappenbeck · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
Functional and Therapeutic Significance of PLK4 in Melanoma
$520,204Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2024 · CA
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
$520,199Gabriel Oliveira Sawakuchi · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
$520,199Gabriel Oliveira Sawakuchi · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Canine Immuno Neurotherapeutics
$520,152M R Chambers · University Of Alabama At Birmingham · U01 · FY2020 · CA
Canine Immuno Neurotherapeutics
$520,152M R Chambers · University Of Alabama At Birmingham · U01 · FY2021 · CA
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
$520,008Sandi Alexander Kwee · Queen'S Medical Center · R01 · FY2021 · CA
Role of inflammation, innate resistance, and immunity in carcinogenesis
$519,797Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Defining the role of mitochondrial injury in MEK inhibitor cardiotoxicity
$519,681Brian C Jensen · Univ Of North Carolina Chapel Hill · R01 · FY2025 · HL
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
$519,464Jinming Gao · Ut Southwestern Medical Center · U01 · FY2019 · CA
Project 1- Elucidating oncogenic KRAS in PDAC cell signaling, resistance and immunity
$519,415Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2024 · CA
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
$519,368Steven Mark Albelda · University Of Pennsylvania · P01 · FY2018 · CA
Mechanism of estrogen independent proliferation in ER+ breast cancer cells
$519,329Aritro Nath · Beckman Research Institute/City Of Hope · U01 · FY2024 · CA